Lidocaine Market Size, Share, Growth, and Industry Analysis, By Type (Injections, Creams, Ointments, Gels, Aerosol Liquids, others), By Application (PDN Cluster headache, Anesthesia, Pain And Irritation, Hemorrhoids, Postherpetic Neuralgia, Cardiac Arrhythmia, Gastrointestinal Tract Examination, Labor Pain And Discomfort, Nerve Block To Relieve Pain), Regional Insights and Forecast to 2035

Lidocaine Market Overview

The global Lidocaine Market size estimated at USD 1697.59 million in 2026 and is projected to reach USD 3463.53 million by 2035, growing at a CAGR of 8.25% from 2026 to 2035.

The Lidocaine Market is a significant segment of the global local anesthetics and pain management industry. Lidocaine is widely used in surgical procedures, dental treatments, cardiac arrhythmia management, dermatological applications, and chronic pain therapies. More than 320 million surgical procedures are performed globally each year, with lidocaine utilized in a substantial proportion of local anesthesia cases. Approximately 75% of dental anesthetic procedures involve lidocaine-based formulations. The drug is available in multiple dosage forms including injections, creams, gels, ointments, patches, and aerosol solutions. Increasing prevalence of chronic pain conditions affecting over 1.5 billion individuals worldwide continues to support sustained demand for lidocaine products.

The United States represents one of the largest markets for lidocaine products due to extensive healthcare utilization and surgical volumes. More than 51 million inpatient surgical procedures and 48 million outpatient procedures are performed annually across the country. Approximately 80% of dental clinics utilize lidocaine as a primary local anesthetic. Chronic pain affects nearly 51 million adults, creating significant demand for topical lidocaine therapies. More than 7 million antiarrhythmic treatments are administered annually in healthcare facilities where lidocaine remains an important therapeutic option. Growing utilization in dermatology, cosmetic procedures, and ambulatory care settings continues driving market demand throughout the United States.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Surgical procedure demand contributes 72%, chronic pain treatment accounts for 66%, dental anesthesia utilization reaches 75%, outpatient procedures represent 58%, and topical pain therapy adoption exceeds 61%.
• Major Market Restraint: Generic competition affects 47%, pricing pressure reaches 39%, adverse reaction concerns account for 21%, regulatory compliance impacts 26%, and supply chain disruptions contribute 17%.
• Emerging Trends: Topical formulation adoption exceeds 54%, ambulatory procedure utilization reaches 49%, pain management innovation accounts for 41%, dermatology applications contribute 37%, and combination therapies represent 33%.
• Regional Leadership: North America accounts for 38%, Europe contributes 29%, Asia-Pacific represents 25%, Middle East & Africa hold 8%, and hospital utilization exceeds 67%.
• Competitive Landscape: The top five manufacturers control 59%, generic producers account for 62%, pharmaceutical suppliers contribute 48%, specialized anesthetic manufacturers represent 35%, and international suppliers hold 42%.
• Market Segmentation: Injections account for 43%, creams contribute 18%, gels represent 12%, ointments hold 10%, aerosol liquids account for 9%, and other formulations contribute 8%.
• Recent Development: Topical therapy utilization increased 23%, manufacturing efficiency improved 18%, pain management applications expanded 21%, formulation innovation reached 16%, and outpatient procedure adoption grew 19%.

Lidocaine Market Latest Trends

The Lidocaine Market is experiencing substantial growth through increasing use of minimally invasive procedures, pain management therapies, and advanced topical formulations. More than 54% of newly prescribed lidocaine products involve topical delivery systems such as creams, gels, and patches. These formulations improve patient convenience while reducing systemic exposure. Dermatological and cosmetic procedures continue contributing to market expansion. Approximately 35 million aesthetic procedures are performed annually worldwide, with topical anesthetics used in a significant proportion of treatments. Lidocaine-based creams and gels reduce procedural discomfort by nearly 70% during minor dermatological interventions.

Outpatient surgical procedures are another major trend. Nearly 58% of minor surgical interventions now occur in ambulatory care settings where lidocaine remains a preferred anesthetic due to its rapid onset of action. Advanced formulations have improved anesthetic duration by approximately 20% compared with conventional products. Combination therapies are also gaining attention. Lidocaine products combined with anti-inflammatory or analgesic agents account for approximately 33% of new pain management formulations. Digital healthcare platforms are improving prescription management and patient access to topical therapies. These trends continue strengthening the role of lidocaine across anesthesia, pain relief, dermatology, and cardiovascular applications.

Lidocaine Market Dynamics

DRIVER

"Rising demand for local anesthesia and pain management solutions."

The growing number of surgical, dental, and outpatient procedures remains the primary driver of the Lidocaine Market. More than 320 million surgeries are performed globally every year, creating substantial demand for local anesthetics. Approximately 75% of dental anesthetic procedures involve lidocaine-based products because of their proven efficacy and safety profile. Chronic pain conditions affect more than 1.5 billion individuals worldwide, increasing utilization of topical pain management therapies. Ambulatory surgery centers perform nearly 58% of minor procedures using local anesthesia. Lidocaine continues to play a critical role in pain control, procedural anesthesia, and therapeutic interventions across healthcare systems globally.

RESTRAINT

"Intense generic competition and pricing pressure."

Generic pharmaceutical competition remains a significant challenge within the Lidocaine Market. Approximately 47% of manufacturers identify pricing pressure as a key operational concern. Multiple generic suppliers compete across injectable and topical product categories, affecting profit margins and market differentiation. Regulatory compliance requirements add complexity to manufacturing operations. Adverse reactions, although relatively uncommon, occur in approximately 2% of patients receiving lidocaine therapy. Healthcare providers increasingly emphasize cost-effective treatment options, leading to procurement decisions based on pricing rather than brand preference. These factors continue influencing market competitiveness and commercial strategies among manufacturers.

OPPORTUNITY

"Expansion of topical pain management therapies."

Topical pain management represents a major growth opportunity for the Lidocaine Market. Chronic pain affects nearly 20% of the global adult population, creating demand for non-opioid treatment alternatives. More than 54% of new lidocaine prescriptions involve topical formulations such as creams, gels, and patches. Postherpetic neuralgia, neuropathic pain, and musculoskeletal disorders increasingly utilize lidocaine-based therapies. Dermatology clinics and outpatient facilities continue expanding use of topical anesthetics for cosmetic and therapeutic procedures. Advanced delivery technologies improve drug absorption efficiency by approximately 15%, enhancing therapeutic outcomes. Growing preference for localized pain treatment supports continued market expansion.

CHALLENGE

"Maintaining supply stability and regulatory compliance."

Pharmaceutical manufacturers face ongoing challenges related to production consistency and regulatory requirements. Lidocaine production requires strict quality control procedures and compliance with international pharmaceutical standards. Approximately 26% of manufacturers identify regulatory complexity as a major operational challenge. Supply chain disruptions affecting active pharmaceutical ingredients can influence product availability. Healthcare providers require uninterrupted access to anesthetic products because of their essential role in clinical procedures. Manufacturing facilities must continuously invest in quality assurance systems to maintain compliance and product reliability. These challenges continue shaping operational strategies within the Lidocaine Market.

Lidocaine Market Segmentation

Download FREE Sample to learn more about this report.

The Lidocaine Market is segmented by type and application. Injections dominate with approximately 43% market share because of extensive utilization in surgical and dental anesthesia. Creams contribute 18%, while gels account for 12% due to increasing demand for topical pain relief. Ointments represent 10%, aerosol liquids account for 9%, and other formulations contribute 8%. By application, anesthesia remains the leading segment with more than 40% utilization. Pain and irritation treatments contribute approximately 18%, while cardiac arrhythmia management, neuralgia treatment, and nerve block procedures collectively account for significant market demand. Diverse therapeutic applications continue supporting broad market utilization.

BY TYPE

Injections: Lidocaine injections account for approximately 43% of total market demand and remain the most widely used formulation. More than 320 million surgical procedures and millions of dental interventions annually rely on injectable local anesthetics. Lidocaine injections provide rapid onset within 2 minutes and maintain anesthetic effects for approximately 60 minutes in many procedures. Hospitals account for nearly 68% of injectable lidocaine utilization. Dental applications represent approximately 25% of injection demand. Emergency medicine and minor surgical interventions further support consumption. Increasing outpatient procedure volumes and expanding healthcare infrastructure continue strengthening demand for injectable lidocaine products.

Creams: Cream formulations account for approximately 18% of the Lidocaine Market. These products are extensively utilized in dermatology, cosmetic procedures, minor skin surgeries, and pain management therapies. More than 35 million aesthetic procedures performed annually involve topical anesthetic creams. Lidocaine creams reduce procedural discomfort by nearly 70% during dermatological interventions. Approximately 54% of topical lidocaine prescriptions involve cream-based products. Chronic pain treatment applications continue expanding as patients seek non-invasive pain management options. Improved absorption technologies and enhanced patient convenience support continued growth within this segment.

Ointments: Ointments represent approximately 10% of market demand and are commonly used for localized pain relief, hemorrhoid treatment, and minor skin irritation management. More than 40 million individuals globally seek treatment for hemorrhoid-related symptoms each year, supporting demand for lidocaine ointments. Ointment formulations provide prolonged skin contact and improved drug retention compared with some alternative dosage forms. Approximately 45% of hemorrhoid treatment products contain lidocaine as an active ingredient. Healthcare providers continue recommending ointments for targeted symptom management due to their ease of application and localized therapeutic effects.

Gels: Lidocaine gels account for approximately 12% of total market utilization. These formulations are widely employed in urological procedures, gastrointestinal tract examinations, and minor medical interventions. More than 20 million endoscopic procedures are performed annually worldwide, many involving lidocaine gel for patient comfort. Gels provide rapid absorption and effective mucosal anesthesia. Approximately 30% of procedural anesthetic gel products contain lidocaine as the primary active ingredient. Increasing utilization in outpatient settings and diagnostic procedures continues supporting demand for gel-based formulations.

Aerosol Liquids: Aerosol liquid formulations contribute approximately 9% of the Lidocaine Market. These products are utilized in respiratory procedures, minor surgical interventions, and mucosal anesthesia applications. Aerosol delivery systems improve application convenience and provide uniform distribution across treatment areas. Approximately 15 million respiratory diagnostic procedures annually involve topical anesthetic support. Lidocaine aerosol products are frequently used before bronchoscopy and similar interventions. Healthcare providers value aerosol formulations because they reduce direct tissue contact during application and improve patient comfort. Continued growth in diagnostic procedures supports this segment.

Others: Other lidocaine formulations account for approximately 8% of total market demand and include patches, oral solutions, sprays, and combination products. Lidocaine patches are increasingly utilized for neuropathic pain conditions, including postherpetic neuralgia. More than 10 million patients worldwide utilize prescription pain patches annually. Combination formulations incorporating lidocaine and additional therapeutic agents represent approximately 33% of newly developed pain management products. Continuous innovation in drug delivery technologies supports demand for specialized lidocaine formulations across diverse clinical applications.

BY APPLICATION

PDN Cluster Headache: Painful Diabetic Neuropathy (PDN) and cluster headache applications account for approximately 8% of the Lidocaine Market. More than 530 million people globally live with diabetes, and nearly 50% develop some form of neuropathy during their lifetime. Lidocaine formulations are increasingly used for localized neuropathic pain management. Approximately 18% of patients with chronic neuropathic pain receive topical anesthetic therapies as part of treatment plans. Cluster headaches affect nearly 1 in 1,000 individuals, creating demand for fast-acting pain relief solutions. Intranasal lidocaine formulations have demonstrated symptom reduction in approximately 60% of selected cases. Growing prevalence of neuropathic disorders continues supporting demand in this application segment.

Anesthesia: Anesthesia represents the largest application segment, accounting for approximately 41% of the Lidocaine Market. More than 320 million surgical procedures are performed annually worldwide, and local anesthesia remains essential for many interventions. Approximately 75% of dental procedures requiring anesthesia involve lidocaine-based formulations. Hospitals account for nearly 67% of anesthesia-related lidocaine consumption. Lidocaine provides anesthetic onset within 2 minutes and remains effective for approximately 60 minutes in routine procedures. Outpatient surgery centers continue increasing utilization due to rising volumes of minimally invasive interventions. The extensive use of lidocaine in surgery, dentistry, and ambulatory care supports strong demand within this segment.

Pain And Irritation: Pain and irritation management contributes approximately 18% of total market demand. Chronic pain affects more than 1.5 billion individuals globally, increasing utilization of topical anesthetic products. Lidocaine creams, gels, and patches are widely prescribed for musculoskeletal pain, skin irritation, and localized discomfort. Approximately 54% of topical lidocaine prescriptions target pain-related conditions. Dermatological procedures performed on more than 35 million patients annually also rely on lidocaine products to reduce discomfort. Improved topical delivery technologies have enhanced therapeutic effectiveness by nearly 15%, encouraging adoption across outpatient and homecare settings.

Hemorrhoids: Hemorrhoid treatment applications account for approximately 7% of the Lidocaine Market. More than 40 million individuals worldwide seek treatment for hemorrhoidal symptoms each year. Lidocaine ointments and creams are frequently used to relieve pain, itching, and irritation associated with hemorrhoids. Approximately 45% of over-the-counter hemorrhoid treatment products contain lidocaine. The prevalence of hemorrhoidal disease increases significantly among adults over 50 years of age, affecting nearly 50% of this population segment. Growing awareness of self-care treatment options and increased availability of topical formulations continue supporting demand in this application category.

Postherpetic Neuralgia: Postherpetic neuralgia contributes approximately 9% of total market demand. More than 1 million shingles cases occur annually in major healthcare markets, and approximately 15% of affected patients develop postherpetic neuralgia. Lidocaine patches are widely recognized as an important non-opioid treatment option for localized neuropathic pain. Approximately 60% of postherpetic neuralgia patients receiving topical therapy utilize lidocaine-based products. Advanced patch technologies provide continuous pain relief for up to 12 hours per application. Increasing prevalence of age-related neuropathic disorders continues driving utilization of lidocaine products in this therapeutic area.

Cardiac Arrhythmia: Cardiac arrhythmia applications account for approximately 6% of the Lidocaine Market. Lidocaine remains an important antiarrhythmic agent in emergency and critical care settings. More than 33 million individuals worldwide experience cardiac rhythm disorders annually. Intravenous lidocaine is commonly used in management of ventricular arrhythmias, particularly during acute cardiac events. Hospitals account for nearly 90% of lidocaine utilization in arrhythmia treatment. Approximately 7 million antiarrhythmic interventions annually involve lidocaine therapy in selected healthcare systems. Continued utilization in emergency medicine supports stable demand for injectable formulations.

Gastrointestinal Tract Examination: Gastrointestinal tract examination applications represent approximately 4% of total market demand. More than 20 million endoscopic procedures are performed annually worldwide, many requiring topical anesthesia to improve patient comfort. Lidocaine gels and sprays are widely used before upper gastrointestinal examinations. Approximately 70% of endoscopy centers utilize lidocaine-containing products during diagnostic procedures. These formulations reduce discomfort and improve procedural tolerance by nearly 40%. Growing screening programs for gastrointestinal diseases and increasing endoscopic procedure volumes continue supporting demand for lidocaine-based anesthetic products.

Labor Pain And Discomfort: Labor pain and discomfort applications account for approximately 3% of the Lidocaine Market. More than 130 million births occur globally each year, creating demand for pain management solutions in obstetric care. Lidocaine is commonly utilized during episiotomy procedures and minor obstetric interventions. Approximately 35% of localized obstetric anesthetic procedures involve lidocaine formulations. Hospitals remain the dominant end-users, accounting for more than 90% of demand in this segment. Continued emphasis on maternal comfort and safe pain management options supports utilization within obstetric healthcare settings.

Nerve Block To Relieve Pain: Nerve block procedures account for approximately 4% of market demand. More than 25 million pain management interventions annually involve peripheral or regional nerve blocks. Lidocaine remains one of the most frequently utilized anesthetics because of its rapid onset and reliable performance. Approximately 62% of short-duration nerve block procedures utilize lidocaine formulations. Chronic pain clinics, orthopedic centers, and surgical facilities continue expanding utilization of nerve block therapies. Increased adoption of interventional pain management techniques supports long-term demand within this segment.

Lidocaine Market Regional Outlook

Download FREE Sample to learn more about this report.

The Lidocaine Market demonstrates strong global demand driven by surgical procedures, chronic pain management, dental anesthesia, and cardiovascular applications. North America leads with approximately 38% market share because of advanced healthcare infrastructure and high procedural volumes. Europe contributes 29%, supported by extensive hospital networks and pharmaceutical utilization. Asia-Pacific accounts for 25% due to expanding healthcare access and rising surgical procedure rates. Middle East & Africa represent 8% of market activity, supported by healthcare modernization initiatives. Growing demand for local anesthesia and non-opioid pain management continues supporting market expansion across all major regions.

NORTH AMERICA

North America accounts for approximately 38% of the global Lidocaine Market. The region benefits from extensive healthcare infrastructure, high surgical procedure volumes, and widespread utilization of local anesthetics. The United States contributes approximately 84% of regional demand, while Canada accounts for 11% and Mexico contributes 5%. More than 99 million surgical procedures are performed annually across North America. Approximately 80% of dental clinics utilize lidocaine as their primary anesthetic product. Chronic pain affects nearly 51 million adults in the United States alone, supporting substantial demand for topical pain therapies. Hospitals account for approximately 67% of regional lidocaine consumption. Outpatient surgery centers perform more than 58% of minor procedures using local anesthesia. Dermatological and cosmetic applications continue expanding, with over 15 million aesthetic procedures annually utilizing lidocaine-containing products. Advanced pharmaceutical manufacturing capabilities ensure reliable supply of injectable and topical formulations. Increasing utilization of non-opioid pain management strategies and growing awareness of localized anesthetic therapies continue strengthening North America's leadership position within the Lidocaine Market.

EUROPE

Europe represents approximately 29% of global Lidocaine Market demand. Germany contributes approximately 22% of regional utilization, followed by France at 17%, the United Kingdom at 16%, Italy at 13%, and Spain at 9%. More than 80 million surgical procedures are performed annually throughout Europe. Approximately 73% of dental anesthetic interventions involve lidocaine-based products. Chronic pain conditions affect nearly 20% of the adult population, increasing utilization of topical pain management therapies. Hospitals account for approximately 64% of regional demand, while ambulatory care facilities contribute 24%. Lidocaine patches and topical formulations continue gaining popularity because they provide localized treatment while minimizing systemic exposure. Postherpetic neuralgia treatment accounts for approximately 9% of regional lidocaine utilization. Regulatory support for generic medicines has expanded access to affordable lidocaine products. Pharmaceutical manufacturers continue investing in advanced topical delivery technologies and combination therapies. These factors support stable growth across healthcare systems throughout Europe.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 25% of the global Lidocaine Market and represents one of the fastest-expanding healthcare regions. China contributes approximately 41% of regional demand, followed by Japan at 18%, India at 16%, and South Korea at 7%. More than 120 million surgical procedures are performed annually throughout Asia-Pacific healthcare systems. Rising healthcare expenditures and expanding hospital infrastructure continue increasing access to anesthesia products. Approximately 68% of major hospitals utilize lidocaine as a standard local anesthetic. Dental procedures account for nearly 28% of regional lidocaine utilization. Chronic pain prevalence continues increasing as aging populations expand across several countries. More than 200 million individuals within the region experience chronic pain conditions requiring treatment. Generic pharmaceutical manufacturing plays a major role in market supply. Healthcare modernization initiatives and increasing outpatient procedure volumes continue supporting growth. Expanding access to surgical care, diagnostics, and pain management therapies strengthens regional demand for lidocaine products.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 8% of global Lidocaine Market activity. Healthcare modernization programs, growing surgical procedure volumes, and expanding pharmaceutical access continue supporting regional demand. Gulf countries contribute approximately 57% of regional utilization, while African markets account for 43%. More than 12 million surgical procedures are performed annually throughout the region. Hospitals represent approximately 71% of total lidocaine consumption. Dental healthcare expansion has increased demand for local anesthetics by approximately 18% during recent years. Chronic pain management services are also expanding, particularly within urban healthcare centers. Approximately 35% of newly established specialty clinics offer interventional pain management services utilizing lidocaine-based therapies. Governments continue investing in healthcare infrastructure, pharmaceutical distribution, and medical training programs. Increased access to anesthesia products and pain management treatments supports market development across the region. Growing awareness of localized anesthetic therapies and expanding healthcare services continue creating opportunities for lidocaine manufacturers.

List of Top Lidocaine Companies

• Jichuan Pharma
• Delta Synthetic
• Shreeji Pharma International
• Technodrugs and Intermediates
• Syn Tech Chem and Pharm
• SIMS srl
• Cambrex Karlskoga AB
• Moehs Iberica

List of Top 2 Companies Market Share

• Cambrex Karlskoga AB: Holds approximately 16% market share in lidocaine active pharmaceutical ingredient production, supported by large-scale manufacturing capabilities and supply agreements across multiple pharmaceutical markets.
• Moehs Iberica: Accounts for approximately 13% market share, supported by production of high-purity pharmaceutical ingredients and distribution to more than 50 countries worldwide.

Investment Analysis and Opportunities

Investment activity within the Lidocaine Market continues expanding because of increasing demand for local anesthesia, chronic pain management, and outpatient medical procedures. More than 320 million surgical procedures and 35 million cosmetic procedures are performed globally each year, creating substantial demand for lidocaine products. Topical therapies present a major investment opportunity. Approximately 54% of new lidocaine prescriptions involve creams, gels, patches, or ointments. Chronic pain affects over 1.5 billion individuals worldwide, encouraging development of non-opioid treatment solutions. Pharmaceutical manufacturers continue investing in advanced topical delivery technologies that improve absorption efficiency by nearly 15%.

Outpatient healthcare expansion is another key opportunity. Nearly 58% of minor surgical procedures now occur in ambulatory settings where lidocaine remains a preferred anesthetic. Growth in dermatology, cosmetic medicine, and interventional pain management further strengthens demand. Investments in generic pharmaceutical production continue increasing due to high procedure volumes and stable clinical demand. Expanding healthcare infrastructure in emerging markets creates additional opportunities for manufacturers seeking broader market penetration and production capacity expansion.

New Product Development

Innovation within the Lidocaine Market focuses on advanced delivery systems, improved patient convenience, and enhanced therapeutic effectiveness. More than 33% of newly developed formulations involve combination therapies incorporating lidocaine with anti-inflammatory or analgesic compounds. Topical delivery technologies remain a major innovation area. Advanced creams and gels improve drug absorption by approximately 15% while reducing application frequency. Lidocaine patches capable of providing pain relief for up to 12 hours continue gaining popularity in neuropathic pain management.

Manufacturers are developing novel aerosol formulations that improve distribution uniformity by approximately 20% during mucosal anesthesia applications. Enhanced formulations for dermatological procedures reduce discomfort by nearly 70% while improving procedural efficiency. Research also focuses on controlled-release technologies that extend anesthetic duration by approximately 20%. Pharmaceutical developers continue evaluating new combinations designed to improve outcomes in chronic pain, neuralgia, and postoperative recovery. These innovations strengthen product differentiation and expand clinical applications for lidocaine therapies.

Five Recent Developments

• 2023: Cambrex Karlskoga AB expanded pharmaceutical ingredient production capacity by approximately 18% to support increasing global demand for lidocaine formulations.
• 2023: Moehs Iberica introduced enhanced purification technologies that improved active ingredient consistency by approximately 14%.
• 2024: Shreeji Pharma International increased manufacturing efficiency by 16% through advanced process optimization systems.
• 2024: Technodrugs and Intermediates launched upgraded pharmaceutical-grade lidocaine materials designed to improve formulation stability by approximately 12%.
• 2025: Jichuan Pharma expanded topical lidocaine product development programs, improving bioavailability performance by approximately 15% in selected formulations.

Report Coverage of Lidocaine Market

The Lidocaine Market report provides comprehensive analysis of local anesthetic utilization, pharmaceutical manufacturing trends, therapeutic applications, regional demand patterns, and competitive developments. The study evaluates lidocaine products used across surgery, dentistry, dermatology, cardiovascular care, pain management, and diagnostic procedures.

The report covers injections, creams, ointments, gels, aerosol liquids, and specialized formulations. Injections account for approximately 43% of total demand, while creams contribute 18%, gels represent 12%, ointments hold 10%, aerosol liquids account for 9%, and other formulations contribute 8%. Application analysis includes anesthesia at 41%, pain and irritation at 18%, postherpetic neuralgia at 9%, PDN cluster headache at 8%, hemorrhoids at 7%, cardiac arrhythmia at 6%, gastrointestinal examinations at 4%, nerve block procedures at 4%, and labor pain applications at 3%.